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Mice with Disrupted Type I Protein Kinase A Anchoring in
T Cells Resist Retrovirus-Induced Immunodeficiency
Randi Mosenden,*,†,1 Pratibha Singh,‡,1 Isabelle Cornez,*,† Mikael Heglind,x Anja Ruppelt,*,2
Michel Moutschen,‡ Sven Enerba¨ck,x Souad Rahmouni,‡ and Kjetil Taske´n*,†
Type I protein kinase A (PKA) is targeted to the TCR-proximal signaling machinery by the A-kinase anchoring protein ezrin and
negatively regulates T cell immune function through activation of the C-terminal Src kinase. RI anchoring disruptor (RIAD) is
a high-affinity competitor peptide that specifically displaces type I PKA from A-kinase anchoring proteins. In this study, we
disrupted type I PKA anchoring in peripheral T cells by expressing a soluble ezrin fragment with RIAD inserted in place of the
endogenous A-kinase binding domain under the lck distal promoter in mice. Peripheral T cells from mice expressing the RIAD
fusion protein (RIAD-transgenic mice) displayed augmented basal and TCR-activated signaling, enhanced T cell responsiveness
assessed as IL-2 secretion, and reduced sensitivity to PGE2- and cAMP-mediated inhibition of T cell function. Hyperactivation of
the cAMP–type I PKA pathway is involved in the T cell dysfunction of HIV infection, as well as murine AIDS, a disease model
induced by infection of C57BL/6 mice with LP-BM5, a mixture of attenuated murine leukemia viruses. LP-BM5–infected RIAD-
transgenic mice resist progression of murine AIDS and have improved viral control. This underscores the cAMP–type I PKA
pathway in T cells as a putative target for therapeutic intervention in immunodeficiency diseases. The Journal of Immunology,
2011, 186: 5119–5130.
T
cells are key players in the adaptive immune system,
protecting us against infectious agents and cancer. Ex-
aggerated T cell activity, in contrast, may lead to auto-
immune disease. It is therefore essential that the T cell immune
response is tightly regulated. cAMP negatively regulates T cell
immune function through activation of protein kinase A (PKA) (1).
Type I PKA (regulatory subunit [R]Ia2 catalytic subunit [C]2) is
the predominant PKA isoform in T cells (2, 3). Furthermore,
whereas type II PKA (RIIa2C2) is located at the centrosome, type
I PKA is anchored close to the TCR (4) in lipid rafts, where it
enhances the activity of C-terminal Src kinase (Csk) by phos-
phorylation on S364 (1). Csk is recruited to lipid rafts through
interaction with the phosphorylated transmembrane adaptor pro-
tein phosphoprotein associated with glycosphingolipid-enriched
microdomains (PAG) (5, 6) and represents the most TCR-proximal
PKA substrate in T cells. Activated Csk negatively regulates Src
family tyrosine kinase activity (7, 8) and thereby downregulates
T cell activation.
PKA is assembled into multiprotein signaling complexes with
its selected substrates at particular subcellular locations by A-kinase
anchoring proteins (AKAPs), scaffold proteins that provide
specificity in cAMP signaling. We have identified ezrin as the
functionally important AKAP for type I PKA in T cell lipid rafts
(9). Ezrin is a cytoskeletal adaptor protein that provides a link
between the actin cytoskeleton and the cell membrane, and
thereby governs membrane structure and organization. Ezrin has
an N-terminal band 4.1 ezrin/radixin/moesin domain through
which it interacts with PAG via ezrin/radixin/moesin-binding
phosphoprotein of 50 kDa (EBP50) (10–12), a central a-helical
region spanning the A-kinase binding domain (AKB) (9) and a C-
terminal actin binding domain (13). Thus, type I PKA is targeted
to Csk via the ezrin–EBP50–PAG scaffold complex.
Murine AIDS (MAIDS) occurs postinfection of C57BL/6 mice
with LP-BM5, a complex mixture of murine leukemia viruses
(MuLVs) that includes replication-competent ecotropic-inducing
and mink cell focus-inducing, and replication-defective (BM5def)
MuLVs (14, 15). The disease is characterized by initial lymp-
hoproliferation affecting both T and B cells, hypergamma-
globulinemia, development of splenomegaly and lymphadenop-
athy, followed by severe T cell anergy and immunodeficiency,
leading to increased susceptibility to opportunistic infections,
neoplasms, and ultimately death at 16–24 wk postinfection. Hy-
peractivation of the cAMP–type I PKA pathway is involved in the
T cell dysfunction in MAIDS (16, 17), as well as HIV infection
(18). Blocking this pathway partially restores T cell function
in vitro in MAIDS (16, 17) and in HIV infection (18). Thus, al-
though the MAIDS model is quite distinct from the virology and
biology implicated in HIV infection, it is a suitable model for
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the cAMP- and type I PKA-mediated T cell dysfunction of HIV
infection.
We have previously reported the design of the RI anchoring
disruptor (RIAD) peptide that specifically displaces type I PKA
from lipid rafts and downregulates cAMP-mediated inhibition of
primary human T cell function (19). We have also identified an
additional PKA-binding determinant, RI specifier region (RISR),
upstream of the traditional AKB in the dual-specificity AKAP
ezrin. The RISR acts in synergy with the AKB to enhance an-
choring of type I PKA (20). In this article, we explore the effects
of perturbing the inhibitory cAMP–type I PKA pathway in mouse
peripheral T cells by introducing RIAD in the context of a soluble
ezrin fragment containing the endogenous RISR under control of
the lck distal promoter in mice. Peripheral T cells from RIAD-
transgenic mice displayed enhanced T cell signaling and re-
sponsiveness. Furthermore, peripheral T cells from RIAD-trans-
genic mice were less sensitive to cAMP-mediated inhibition of
T cell immune function. On LP-BM5 infection, the RIAD-
transgenic mice showed resistance to development of MAIDS-
associated splenomegaly, lymphadenopathy, and T cell anergy,
and viral load was also lower. Furthermore, the emergence of
MAIDS phenotypic characteristics was dampened.
Materials and Methods
Engineering of the transgene construct and generation of
transgenic mice
Nt 934–1236 were PCR-amplified from human ezrin cDNA, introducing
new 59 BamHI and 39 NheI restriction sites, and fused to an oligonucle-
otide consisting of the RIAD sequence in frame with a hemagglutinin (HA)
epitope tag flanked by 59 NheI and 39 BamHI restriction sites. The resulting
construction, referred to as the RIAD construct, was verified by sequenc-
ing. For mammalian cell expression, a Kozak sequence (21) was engi-
neered in front of the ATG and a stop codon added on insertion into the
pFLAG-CMV-5a vector. The RIAD construct was also inserted between
the mouse lck distal promoter and introns and exons of the human growth
hormone gene (included to increase transgene expression) (22, 23) of the
pW120 vector (24, 25) to create pW120 w/RIAD.
Vector-derived sequences were removed by restriction digestion and gel
purification, and the promoter-open reading frame fragment was used to
make RIAD-transgenic mice on a C57BL/6 3 CBA background by pro-
nuclear microinjection as described previously (26–28). RIAD-transgenic
founder mice were crossed on the C57BL/6 background for up to 10
generations under specific pathogen-free conditions at the animal facility
at Department of Medical and Clinical Genetics, Institute of Biomedicine,
University of Gothenburg, Gothenburg, Sweden, the National Lab Animal
Center at the Norwegian Institute of Public Health, Oslo, Norway, and the
Interdisciplinary Cluster for Applied Genoproteomics (GIGA-R) animal
facility at University of Lie`ge, Laboratory of Immunology and Infectious
Diseases, Lie`ge-Sart Tilman, Belgium. Mice were weighed before being
sacrificed by cervical dislocation. For genotyping, tail or ear biopsies were
incubated in 100 ml of 25 mM NaOH and 0.2 mM EDTA at 95˚C for 20
min. After incubation, an equal volume of 40 mM Tris-HCl was added and
the solution mixed. PCR genotyping was performed using primers 59-
CCCTCAGGAGACAGGAAGTCAG-39, 59-CCTAAGGTGGGAAATGA-
TGGACAG-39, and 59-GCAGCATCAACTCCTCCTTCTC-39, and Accu-
Prime Pfx Supermix (Invitrogen). Products and DNA sizing ladder (Low
DNA Mass Ladder; Invitrogen) were separated by agarose gel electro-
phoresis and visualized using Gel Star Nucleic Acid Gel Stain (Invitrogen).
Animal care was in accordance with national legislation and institutional
guidelines. All use of animals has been approved and registered by na-
tional animal research authorities.
Cell culture and transient transfections
COS-7 cells were maintained in DMEM GlutaMAX supplemented with
10% FBS, 1 mM sodium pyruvate, 1:100 MEM nonessential amino acids,
100 U/ml penicillin, and 100 mg/ml streptomycin (all from Invitrogen)
(complete medium). At 90% confluence, the cells were transfected with 10
mg pFLAG-CMV-5a containing the RIAD construct per 56.7-cm2 culture
dish using FuGENE 6 Transfection Reagent (Roche). After 24 h, the cells
were lysed in 50 mM Tris (pH 7.4), 100 mM NaCl, 5 mM EDTA, and 1%
Triton X-100 with 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM
Na3VO4, and 1 mM PMSF (lysis buffer).
Jurkat TAg, a derivative of the human leukemic T cell line Jurkat stably
transfected with the SV40 large TAg (29), was kept at logarithmic growth
in RPMI 1640 GlutaMAX (Invitrogen) complete medium. For transfec-
tions, 23 107 cells in OPTI-MEM (Invitrogen) were mixed with 40–80 mg
pW120 w/RIAD in electroporation cuvettes with a 0.4-cm electrode gap
(Bio-Rad) and subjected to an electric field of 250 V/cm with 950 mF
capacitance. The cells were expanded in RPMI 1640 GlutaMAX complete
medium for 20 h before harvest in lysis buffer.
Immunoprecipitations
For immunoprecipitations, COS-7 cell lysates were precleared with mouse
g-globulin (Jackson ImmunoResearch) and protein A/G PLUS-agarose
immunoprecipitation reagent (Santa Cruz Biotechnology) at 4˚C for 30
min. The lysates were transferred to new tubes, and Ab against HA (16B12;
BioSite), RIa (4D7) (4, 30), or mouse g-globulin as a control and protein
A/G PLUS-agarose immunoprecipitation reagent were added and incuba-
tion at 4˚C continued overnight. Subsequently, immune complexes were
washed once in lysis buffer and subjected to SDS-PAGE and immuno-
blotting.
Far Western analyses with radiolabeled R (R overlays)
Jurkat TAg or mouse splenic T cell lysates were subjected to SDS-PAGE
and R overlays were conducted as described previously (31), using 32P-
labeled recombinant bovine RIa (A98S), substituted to allow autophos-
phorylation (19, 32), or recombinant mouse RIIa (33). In brief, the mem-
brane with immobilized protein was blocked in 5% nonfat dry milk/0.1%
BSA/TBST (blotto). Purified recombinant R (2 mg) was radiolabeled using
purified C (1.5 mg) and [g-32P]ATP (0.05 mCi; PerkinElmer) in 50 mM
MOPS (pH 6.8), 50 mM NaCl, 2 mM MgCl2, and 1 mM DTT at 37˚C for
30–45 min, and separated from free [g-32P]ATP by gel filtration (NICK
Column Sephadex G-50; GE Healthcare). Specific activity was quantified
by liquid scintillation counting (1600TR Tri-Carb; Packard Instrument).
All overlays were performed overnight at room temperature using 1 3 106
cpm/ml TBST. The membrane was washed in TBST five times and signal
detected by autoradiography.
Isolation of lipid rafts
Purification of lipid rafts from Jurkat TAg lysates by density gradient
centrifugation was performed as described previously (34). The peak raft
fractions were pooled and subjected to SDS-PAGE and immunoblotting.
Densitometry measurements were done using Quantity One 4.5 (Bio-Rad).
SDS-PAGE and immunoblotting
Immune complexes from immunoprecipitations, cell or tissue lysates, or
pooled peak raft fractions were separated by SDS-PAGE and transferred to
PVDF membranes by electroblotting. Membranes were blocked in 5%
nonfat dry milk/TBST or 3% BSA/TBST for phospho-Ab at room tem-
perature for 1 h, and incubated at 4˚C overnight with primary Ab diluted in
5% nonfat dry milk/TBST or 3% BSA/TBST for phospho-Ab. Ab used
were against RIa (20; BD Biosciences), HA (16B12, BioSite or 3F10,
Roche), actin (C-11; Santa Cruz Biotechnology), linker for activation of
T cells (LAT; Upstate Biotechnology), GAPDH (mAbcam 9484; Abcam),
Akt (pT308; Cell Signaling), phosphotyrosine (4G10; Upstate Biotech-
nology), and Src family (pY416; Cell Signaling). For secondary detection,
HRP-conjugated Ab (Jackson ImmunoResearch/GE Healthcare) were used
and membranes were developed using SuperSignal West Pico Chemilu-
minescent Substrate (Pierce)/ECL Detection Reagents (GE Healthcare).
Tissue lysis
Mouse tissues were dissected and transferred to ice-cold 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100. Tissues were
then homogenized using a Polytron PT-3000 (Kinematica). Homogenates
were incubated with slow shaking at 4˚C for 60 min and then centrifuged at
12,0003 g at 4˚C for 10 min. Supernatants were transferred to clean tubes.
Centrifugation and supernatant collection were repeated until the extracts
were clear. Protein concentrations were determined using the Bio-Rad
Protein Assay, based on the method of Bradford, and 20 mg protein was
loaded in each well.
Isolation of T cells from mouse spleen
Spleens were dissected, weighed, and converted into single-cell suspensions
by squeezing through a 100-mm cell strainer (Falcon) in PBS. Erythrocytes
were depleted by lysis in hypotonic buffer (RBC Lysing Buffer; Sigma-













Aldrich). The buffer was neutralized with RPMI 1640 GlutaMAX, and
splenocytes were resuspended in 0.1% BSA/2 mM EDTA/PBS (pH 7.4)
and counted on a Z2 Coulter Particle Count and Size Analyzer (Beckman
Coulter). CD3+ T cells were isolated using Dynal Mouse T Cell Negative
Isolation Kit (Invitrogen) according to the manufacturer’s protocol and
counted. When needed, the cells were lysed in lysis buffer.
Immunofluorescence
For immunofluorescence studies, freshly isolated mouse splenic T cells
were settled on poly-L-lysine (Sigma-Aldrich)–coated coverslips on ice for
30 min. Capping of the TCR was achieved by incubating cells with 1 mg/
ml biotin-conjugated hamster anti-mouse CD3e (145-2C11; BD Bio-
sciences) in 0.1% BSA/PBS on ice for 30 min, followed by transfer to poly
(L-lysine)–coated coverslips and incubation with 10 mg/ml streptavidin,
Alexa Fluor (Ax) 405 conjugate (Invitrogen) in 0.1% BSA/PBS on ice for
30 min, and then at 37˚C for 20 min. The cells were next fixed with 3%
PFA/PBS for 30 min, permeabilized with 0.1% NP-40/PBS for 5 min, and
then blocked with 2% BSA/0.01% Tween 20/PBS for 30 min. Primary Ab
against HA (16B12; BioSite), RIa (4D7), Ca (A-2; Santa Cruz Bio-
technology), and RIIa (M-20; Santa Cruz Biotechnology) in 2% BSA/
0.01% Tween 20/PBS were added for 30 min. The cells were then in-
cubated with fluorochrome-conjugated secondary Ab (Ax488 goat anti-
mouse IgG1, Ax488/546 goat anti-mouse IgG2a, Ax555 goat anti-rabbit
IgG; Invitrogen) in 2% BSA/0.01% Tween 20/PBS for 30 min before being
mounted on glass microscope slides using Fluorescent Mounting Medium
(DakoCytomation). Confocal microscopy was performed with a Zeiss
LSM 510 META confocal microscope with a Plan-Apochromat 63 3 1.4
Oil differential interference contrast objective lens, using laser excitation at
405, 488, and 561 nm. The widths of the emission channels were set such
that bleed through across channels was negligible, and pictures were
obtained using sequential scanning. Relative colocalization was calculated
as total red and green (yellow) divided by total red or green pixels in each
cell using ImageJ software.
Stimulation for phosphostatus analyses
A total of 8 3 107 freshly isolated mouse splenic T cells/ml in RPMI 1640
GlutaMAX were equilibrated at 37˚C for 10 min. The cells were then
activated by the addition of 1 mg/ml biotin-conjugated hamster anti-mouse
CD3e (145-2C11; BD Biosciences) and 1 mg/ml biotin-conjugated rat anti-
mouse CD4 (RM4-5; BD Biosciences), followed by cross-linking with 40
mg/ml avidin (Invitrogen) at 37˚C for the indicated times. Activation was
terminated by transfer to ice and addition of 23 lysis buffer.
Flow cytometry
A total of 1 3 106 freshly isolated mouse splenic T cells were fixed 1:1 in
BD Phosflow Fix Buffer I (BD Biosciences) at 37˚C for 10 min. The cells
were permeabilized in ice-cold BD Phosflow Perm Buffer III (BD Bio-
sciences) and kept at280˚C at least overnight. Subsequently, 0.53 106 cells
were stained with a mixture of Ab against HA (Ax488-conjugated, 6E2; Cell
Signaling), CD8 (allophycocyanin-eFluor 780-conjugated, 53-6.7), FOXP3
(allophycocyanin-conjugated, FJK-16s) (both eBioscience), CD3 (PE-con-
jugated, 17A2), CD4 (PerCP-conjugated, RM4-5), CD45R (PerCP-conju-
gated, RA3-6B2), CD11b (allophycocyanin-conjugated, M1/70), and CD25
(PE-conjugated, PC61) (all from BD Biosciences). After labeling at room
temperature for 30 min, the cells were resuspended in 1% FBS/0.09%
NaN3/PBS before FACS analysis. Regarding lymph node cells, 1 3 10
6
freshly isolated cells were blocked with Ab against CD16/CD32 (FcgRIII/
II, 2.4G2) for 15 min before labeling with Ab against CD4 (PE-conjugated,
GK 1.5 or FITC-conjugated, RM4-5), CD45R (FITC-conjugated, RA3-
6B2), CD11b (PE-conjugated, M1/70), CD3 (allophycocyanin-conju-
gated, 145-2C11), CD90.2 (FITC-conjugated, 30.H12), and CD279 (PE-
conjugated, J43) (all from BD Biosciences). Data were acquired on a
FACSCanto II flow cytometer (BD Biosciences) equipped with 407-, 488-,
and 633-nm lasers. Data were subsequently analyzed using FlowJo soft-
ware (Tree Star).
Cytokine production assays
Freshly isolated mouse splenic T cells were seeded into 96-well flat-bottom
plates at a concentration of 2 3 106 cells/ml in RPMI 1640 GlutaMAX
complete medium and incubated with increasing concentrations of 8-(4-
chlorophenylthio)-cAMP (8-CPT-cAMP; BioLog Life Science) or PGE2
(Sigma-Aldrich) at 37˚C for 30 min before stimulation with Dynabeads
Mouse CD3/CD28 T Cell Expander (Invitrogen) at cell/bead ratio 1:1 at
37˚C for 20 h. Cell-free supernatants were harvested and cytokine levels
quantified by ELISA (IL-2; R&D Systems) or using a Bio-Plex System
(Bio-Rad) and a Bio-Plex Mouse Cytokine Th1/Th2 Panel (Bio-Rad),
allowing for the multiplexed detection of mouse IL-4, IL-5, IL-10, IL-
12, GM-CSF, IFN-g, and TNF-a in each sample. The assays were per-
formed in accordance with the manufacturer’s instructions. The IC50 val-
ues, defined as the concentration of 8-CPT-cAMP/PGE2 needed to inhibit
IL-2 production by 50%, were estimated by nonlinear regression analyses
using SigmaPlot (SPSS).
Virus
The LP-BM5–producing SC-1/MuLV cell line (AIDS Research and Ref-
erence Reagent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases, National Institutes of Health), established by
cocultivation of SC-1 cells with mitomycin C-treated cells obtained from
the enlarged lymph nodes of a C57BL/6 mouse inoculated with virus
harvested from a reticulum cell neoplasm-BM5 stromal cell line estab-
lished by Haas and Reshef (35), was maintained in accordance with the
protocol provided. In brief, SC-1/MuLV cells were grown in DMEM
GlutaMAX complete medium, and viruses were extracted from the su-
pernatant of confluent cells and stored in liquid nitrogen.
Induction of MAIDS and isolation of lymph node cells
Six- to 8-wk-old RIAD-transgenic mice and sex-matched wild-type lit-
termates were injected four times i.p. at 1-wk intervals with 0.5 ml viral
extract. Age- and sex-matched C57BL/6 control mice were correspondingly
injected with 0.5 ml PBS. Eight to 9 wk after the last injection, the mice
were sacrificed by cervical dislocation. Spleens and lymph nodes (cervical,
mesenteric, inguinal, and axillary) were dissected and weighed. Inguinal
and axillary lymph nodes were converted into single-cell suspensions by
squeezing through a 100-mm cell strainer (Falcon); lymph node cells were
washed three times in RPMI 1640 complete medium and counted on a
Thoma cytometer (Mariefeld) after trypan blue (Invitrogen) exclusion.
Proliferation assays
Freshly isolated mouse lymph node cells were seeded into 96-well flat-
bottom plates at a concentration of 1 3 106 cells/ml in RPMI 1640 sup-
plemented with 10% FBS, 1025 M 2-ME, 1 mM sodium pyruvate, 1:100
MEM nonessential amino acids, 60 U/ml penicillin, and 60 mg/ml strep-
tomycin (all from Invitrogen) and stimulated with 5 mg/ml CD3 Ab (145-
2C11; BD Biosciences) and/or 50 U/ml IL-2 (Roche) at 37˚C for 72 h. A
total of 0.4 mCi [3H]thymidine (PerkinElmer) was included for the last 4 h.
Cells were harvested (Filter Mate; PerkinElmer) and proliferation was
quantified using TopCount NXT Microplate Scintillation and Lumines-
cence Counter (PerkinElmer).
RNA extraction, reverse transcription, and quantitative
real-time PCR
RNA was extracted from mouse lymph nodes using TRIzol, reversely
transcribed (1 mg) using Expand Reverse Transcriptase, and quantitative
real-time PCR was performed using 2 ml diluted cDNA (1:1000), primers
59-CCTCCTAAGTCCCGGGTTCTC-39 and 59-CGGCCGCCTCTTCTTA-
ACT-39 for BM5def and 59-CACCCCACTGAGACTGATACA-39 and 59-
TGATGCTTGATCACATGTCTCG-39 for B2M and SYBR Green PCR
Master Mix (all from Roche) in accordance with the manufacturer’s in-
structions. All PCR was performed on LightCycler Systems for real-time
PCR (Roche).
Statistics
Graphs were made in SigmaPlot 8.0 (SPSS). Statistical analyses were per-
formed using the Mann–Whitney U test, conducted in SPSS 16.0 for Win-
dows. Results are given as medians and 25th percentiles unless otherwise
stated. The two-sided p values were considered statistically significant at
p , 0.05.
Results
Engineering of T cell-specific disruption of type I PKA
anchoring
Given the demonstrated role of lipid raft-targeted type I PKA in
cAMP-mediated modulation of T cell immune function (1, 9), we
wanted to explore the outcome of competing the anchoring of type
I PKA to T cell lipid rafts by its AKAP ezrin in a physiological
context. We engineered a construct comprising aa 312–413 from
the a-helical region of ezrin (including the endogenous RISR)













with the high-affinity RI-specific RIAD inserted in the position of
the endogenous AKB and a C-terminal HA epitope tag (see boxed
areas in Fig. 1B). To examine the function of RIAD in the context
of the soluble ezrin fragment containing the endogenous RISR,
COS-7 cells expressing this RIAD fusion protein under the CMV
promoter were lysed and subjected to immunoprecipitations with
Ab to the HA epitope and RIa (Fig. 1A). In such experiments,
endogenous RI coimmunoprecipitated with the RIAD fusion pro-
tein and vice versa. Control immunoprecipitations with mouse IgG
were negative (data not shown). Thus, the RIAD fusion protein
binds type I PKA inside cells.
We next expressed the RIAD fusion protein under the mouse lck
distal promoter (pW120 w/RIAD; Fig. 1B) in Jurkat TAg cells.
Lysates from transfected cells were subjected to SDS-PAGE and
R overlay, demonstrating strong binding of the expressed RIAD
fusion protein to radiolabeled RI but not RII (Fig. 1C).
Lipid rafts were isolated from pW120 w/RIAD-transfected
Jurkat TAg cell lysates by sucrose gradient centrifugation and
assessed for levels of RI (Fig. 1D, upper panel). In cells expressing
the RIAD fusion protein, levels of lipid raft associated RI were
reduced by 62.5% compared with untransfected cells (Fig. 1D,
1E). LAT, a lipid raft-associated adaptor protein (36), was used as
an internal standard (Fig. 1D, lower panel, 1E). In conclusion,
expression of the RIAD fusion protein under the lck distal pro-
moter leads to displacement of type I PKA from T cell lipid rafts.
Generation of RIAD-transgenic mice
After verification of the ability of the RIAD fusion protein ex-
pressed in T cells under the lck distal promoter to displace type I
PKA from lipid rafts, we linearized the construct, removed vector-
derived sequences, and used the promoter-open reading frame
fragment to make RIAD-transgenic mice on a C57BL/6 3 CBA
background by pronuclear microinjection. Five founder animals
were identified using a PCR assay designed to give products of
205 and 335 bp for RIAD-transgenic and wild-type mice, re-
spectively (Fig. 2A). Satisfactory expression of the RIAD fusion
protein was identified in RIAD-transgenic lines 11 (high expres-
sion) and 16 (medium expression) as evident from HA immuno-
blotting of spleen protein extracts (Fig. 2B). The expression pat-
tern of the RIAD fusion protein in RIAD-transgenic line 11 was
further investigated by HA immunoblotting of protein extracts
from various organs and tissues (Fig. 2C, upper panel ). A GAPDH
immunoblot was included as a control for loading and integrity of
samples (Fig. 2C, lower panel). Expression of the RIAD fusion
protein was observed in spleen and lymph nodes, as well as in
thymus, lung, and small intestine (low levels), which is compatible
with the notion of a T cell-specific expression directed by the
mouse lck distal promoter (25, 37, 38).
CD3+ T cells were negatively selected from a single-cell sus-
pension of mixed spleen cells from RIAD-transgenic and wild-
type mice, and expression of the RIAD fusion protein assessed by
flow cytometry using fluorochrome-conjugated Ab to CD3 and
HA (Fig. 2D). Generally, 90–97% of the CD3+ cells expressed the
RIAD fusion protein.
Immunofluorescence studies revealed that the RIAD fusion pro-
tein (Fig. 2Eb, 2Ee, 2Eh) colocalized with PKA RI (Fig. 2Ea, 2Ec)
and PKA C (Fig. 2Ed, 2Ef) in splenic T cells from RIAD-trans-
genic mice. In contrast, PKA RII (Fig. 2Eg) localized to the cen-
trosome as earlier reported (19, 39) and did not colocalize with
the RIAD fusion protein (Fig. 2Ei). Hence the RIAD fusion pro-
tein colocalizes with type I PKA in mouse peripheral T cells.
Splenic T cell lysates from RIAD-transgenic and wild-type mice
FIGURE 1. RIAD in the context of a soluble ezrin fragment containing the endogenous RISR is expressed in T cells under the lck distal promoter and
displaces type I PKA from lipid rafts. A, COS-7 cells were transfected with 10 mg pFLAG-CMV-5a containing an ezrin fragment encompassing the
endogenous RISR coupled to RIAD (see B) or left untransfected. The HA-tagged RIAD fusion protein and endogenous RIa were immunoprecipitated from
precleared cell lysates (IP). Precipitates were subjected to SDS-PAGE and immunoblotting with the indicated Ab (IB). Expression of the HA-tagged RIAD
fusion protein and equal levels of endogenous RIa and actin (loading control) in whole cell lysates (WCL) were confirmed by immunoblotting. B,
Schematic presentation of the RIAD construct under the mouse lck distal promoter in pW120 (pW120 w/RIAD). Amino acid numbers are indicated. hGH,
human growth hormone gene. C, Jurkat TAg cells were transfected with 80 mg pW120 w/RIAD or left untransfected. Cell lysates were subjected to SDS-
PAGE and analyzed for R binding by [32P]-RIa and [32P]-RIIa overlay (O). Expression of the HA-tagged RIAD fusion protein and equal levels of actin
(loading control) were confirmed by immunoblotting (IB). D and E, Jurkat TAg cells were transfected with 40 mg pW120 w/RIAD or left untransfected.
The cells were lysed and lipid rafts isolated as described in Materials and Methods. Peak raft fractions (fractions 1–5) were pooled and relative levels of
RIa in lipid rafts assessed by immunoblotting (D) and measured by densitometry (E, amalgamated data, mean 6 SD). LAT was used as a marker for lipid
rafts and as an internal standard. Data presented in A, C, and D are representative of three experiments.













were subjected to SDS-PAGE and R overlays. The RIAD fusion
protein bound strongly to radiolabeled RI, but not to RII (Fig. 2F).
This confirmed that the RIAD fusion protein interacts specifically
with type I PKA in T cells also when expressed in vivo in mice.
In general, viable heterozygous RIAD-transgenic mice were
born in Mendelian ratios and appeared normal. Spleen T cell
counts were, however, significantly higher in 6- to 8-wk-old RIAD-
transgenic mice when compared with sex-matched wild-type lit-
termates (Fig. 2G). Still, overall spleen weight was not increased
in the RIAD-transgenic mice. Furthermore, the percentages of
CD45R (B220)+ B cells and CD11b+ monocytes/macrophages,
as well as the ratio of CD4+ to CD8+ T cells and the percentage
of regulatory T cells (Tregs) (CD4+CD25+/CD4+FOXP3+ cells),
were not altered in RIAD-transgenic mice compared with sex-
matched wild-type littermates (data not shown).
Augmented TCR-proximal signaling in T cells from
RIAD-transgenic mice
To assess the level of association of type I PKAwith the proximal
TCR signaling machinery during T cell activation, we examined
localization of CD3 (Fig. 3Aa, 3Ad) and RI (Fig. 3Ab, 3Ae) in
splenic T cells from RIAD-transgenic and wild-type mice by
double-immunofluorescent staining. TCR/CD3 cross-ligation led
to activation-dependent capping of CD3 in T cells from both wild-
type and transgenic mice (Fig. 3Aa, 3Ad). Whereas RI colocalized
with the CD3 cap in T cells from wild-type mice (Fig. 3Ac)
consistent with earlier observations (4), RI colocalization with
CD3 was reduced by 38% in T cells from RIAD-transgenic mice
(Fig. 3Af, 3B). Thus, the inhibitory cAMP–type I PKA pathway
appears to be partially disrupted in peripheral T cells from RIAD-
transgenic mice.
We next examined the effect of RI anchoring disruption on
proximal TCR signaling. Although activation by CD3 cross-
ligation is sufficient to trigger TCR-proximal signaling in hu-
man T cells (40), CD4 costimulation is needed in mouse T cells
(R. Mosenden, I. Cornez, K. Tasken, unpublished observations
and Ref. 41). Splenic T cells from 6- to 8-wk-old RIAD-transgenic
mice and sex-matched wild-type littermates were stimulated by
CD3/CD4 cross-ligation and kinetics of phosphorylation of in-
dividual proteins in the TCR signaling cascade assessed by im-
munoblotting for phosphotyrosine, pSrc family (Y416) to detect
phosphorylated lymphocyte-specific protein-tyrosine kinase (pLck;
Y394) and pAkt (T308). The pSrc family (Y416) Ab detects all
Src family protein tyrosine kinases phosphorylated on the con-
served activating tyrosine residue, for example, Y416 in Src and
Y394 in Lck. Expression of the RIAD fusion protein and equal
loading were confirmed by HA epitope and actin immunoblotting,
respectively (Fig. 3C). Amalgamated data from several experi-
ments demonstrated that the basal level of phosphorylation of
FIGURE 2. Expression of the RIAD fusion protein in mice. A, PCR
products from analysis of tail biopsies from RIAD-transgenic (Tg 11) and
wild-type (WT) mice, separated by agarose gel electrophoresis (205 and
335 bp, respectively, compared with DNA ladder). B, Expression of the
HA-tagged RIAD fusion protein in spleens from representative RIAD-
transgenic mice from high (Tg 11) and medium (Tg 16) expressor lines,
assessed by SDS-PAGE (20 mg total protein/lane) and immunoblotting
with HA and actin (loading control) Ab. C, Tissue (indicated) expression
of the HA-tagged RIAD fusion protein in a RIAD-transgenic mouse (Tg
11) assessed by SDS-PAGE (20 mg total protein/lane) and immunoblotting
with HA and GAPDH (control for loading and integrity of samples) Ab. D,
Expression of the HA-tagged RIAD fusion protein in splenic CD3+ T cells
from a representative RIAD-transgenic mouse (Tg 11) assessed by in-
tracellular flow cytometry. E, Splenic T cells from a RIAD-transgenic
mouse (Tg 11) were immunostained for HA (b, e, h), RIa (a), Ca (d), and
RIIa (g). Merged images show overlapping subcellular distribution that
appears yellow for the HA-tagged RIAD fusion protein and RIa (c) and
further Ca (f), but not for the HA-tagged RIAD fusion protein and RIIa (i).
Scale bar, 5 mm. F, Splenic T cells from a RIAD-transgenic mouse (Tg 11)
and a wild-type control (WT) were lysed, subjected to SDS-PAGE, and
analyzed for R binding by [32P]-RIa or [32P]-RIIa overlay (O). Expression
of the RIAD fusion protein and equal loading (actin) were confirmed by
immunoblotting (IB). G, T cell counts in spleens from RIAD-transgenic
mice (Tg 11) and sex-matched wild-type littermates (WT) of indicated age.













Lck was significantly enhanced in RIAD-transgenic mouse T cells
(Fig. 3E). Furthermore, postactivation, CD3z, LAT, ERK, and Akt
were more extensively phosphorylated in T cells from RIAD-
transgenic mice (Fig. 3D, 3F–J). Together, this indicates that
uncoupling of the cAMP negative feedback loop results in en-
hanced TCR signaling in peripheral T cells from RIAD-transgenic
mice.
Enhanced T cell responses in RIAD-transgenic mice
From studies of T cell signaling, we proceeded to examine func-
tional responses of T cells from RIAD-transgenic mice. Splenic
T cells from RIAD-transgenic mice and sex-matched wild-type
littermates were activated by CD3/CD28 cross-ligation for 20 h
and cytokine secretion levels determined. T cells from RIAD-
transgenic mice displayed enhanced immune responsiveness
assessed as IL-2 secretion compared with T cells from wild-type
littermates (Fig. 4A). TNF-a production (Fig. 4H) was also in-
creased in T cells from RIAD-transgenic mice compared with
T cells from wild-type littermates. In comparison, secretion of IL-
4, IL-5, IL-10, IL-12, GM-CSF, and IFN-g (Fig. 4B–G) did not
significantly differ between T cells from RIAD-transgenic mice
and T cells from wild-type littermates. Thus, T cell-specific per-
turbation of the inhibitory cAMP–type I PKA pathway results in
hyperresponsive T cells and increased secretion of the proinflam-
matory cytokine TNF-a in RIAD-transgenic mice, which indicates
that this pathway imposes a tonic level of inhibition on T cell
immune responses.
Altered PGE2 and cAMP sensitivity in T cells from
RIAD-transgenic mice
To determine the effect of RI anchoring disruption on T cell im-
mune function in a situation where extracellular stimuli turn on the
inhibitory cAMP–type I PKA pathway, we preincubated splenic
T cells from 6- to 8-wk-old RIAD-transgenic mice and sex-
matched wild-type littermates with increasing concentrations of
a cell-permeable analog of cAMP, 8-CPT-cAMP, and proceeded
to activate the cells and assess T cell immune responsiveness,
measured as IL-2 secretion. This experiment demonstrated that 8-
FIGURE 3. Displacement of type I PKA
from the TCR-proximal signaling machin-
ery results in enhanced downstream sig-
naling in peripheral T cells from RIAD-
transgenic mice. A, Localization of TCR/
CD3 (a, d) and RIa (b, e) in splenic T cells
from RIAD-transgenic (Tg 11, d–f) and
wild-type (WT, a–c) mice after capping of
the TCR/CD3 using biotin-conjugated CD3
Ab and subsequently fluorochrome-conju-
gated streptavidin as assessed by immuno-
fluorescence analysis. Merged images show
overlapping subcellular distribution that ap-
pears yellow (c, f). Scale bar, 2 mm. B, Anal-
ysis of colocalization of TCR/CD3 and RIa
in activated RIAD-transgenic (Tg 11) and
wild-type (WT) splenic T cells. Colocali-
zation ratios were calculated from double-
positive pixels divided by all stained pixels
(mean 6 SD). C, Splenic T cells from 6-to
8-wk-old RIAD-transgenic mice (Tg 11)
and sex-matched wild-type littermates (WT)
were activated for the indicated periods by
CD3/CD4 Ab cross-ligation. The phosphor-
ylation status of the indicated proteins, ex-
pression of the RIAD fusion protein, and
equal loading (actin) were assessed by SDS-
PAGE and immunoblotting. Data presented
are representative of three experiments.
D–J, Relative levels of phosphorylation from
experiments as in C measured by densi-
tometry (n = 3, mean 6 SEM). Actin was
used as an internal standard.













CPT-cAMP inhibited IL-2 secretion in a concentration-dependent
fashion with an IC50 of 0.4 mM for wild-type T cells. For RIAD-
transgenic T cells, the inhibition curve was right shifted, with
an apparent IC50 of 1.4 mM (Fig. 5A). When 20 pairs of 6- to 8-
wk-old wild-type controls (sex-matched littermates) and RIAD-
transgenic mice were compared, the average IC50 (8-CPT-cAMP)
values for cAMP-mediated inhibition of IL-2 secretion were
0.6 and 1.0 mM, respectively (Fig. 5B). Next, splenic T cells from
a 4- to 5-mo-old RIAD-transgenic mouse and a sex-matched wild-
type littermate were preincubated with increasing concentrations
of PGE2 and subsequently activated via the TCR. PGE2 inhibited
IL-2 secretion in a dose-dependent manner with an IC50 of 1.5 nM
for wild-type T cells. For RIAD-transgenic T cells, the inhibition
curve was right shifted with an IC50 of 29.9 nM (Fig. 5C). We
conclude that peripheral T cells from RIAD-transgenic mice dis-
play a reduced sensitivity to cAMP-mediated inhibition of T cell
function.
Resistance to disease progression in LP-BM5–infected
RIAD-transgenic mice
Because hyperactivation of the cAMP–type I PKA pathway is
involved in the T cell dysfunction in MAIDS (16, 17), as well as
HIV infection (18), we wanted to investigate the consequences
of T cell-specific type I PKA anchoring disruption on MAIDS
disease progression. Six- to 8-wk-old RIAD-transgenic mice and
sex-matched wild-type littermates were injected four times (i.p.)
at 1-wk intervals with LP-BM5 extract. Eight to 9 wk after the last
injection, MAIDS-associated splenomegaly and lymphadenopathy
were apparent in the wild-type mice (Fig. 6A, middle panel), but
clearly less manifest in the RIAD-transgenic mice (Fig. 6A, right
panel). In PBS-injected C57BL/6 control mice, spleen and lymph
node sizes were normal (Fig. 6A, left panel). Spleen (Fig. 6B) and
lymph node (Fig. 6C) weights were significantly lower in LP-
BM5–infected RIAD-transgenic mice compared with LP-BM5–
infected sex-matched wild-type littermates. Thus, MAIDS-associated
spleen and lymph node enlargement is limited in RIAD-transgenic
mice.
The ability of T cells to proliferate in response to CD3 stimu-
lation declines progressively during the course of MAIDS, par-
tially because of high intracellular levels of cAMP and the result-
ing type I PKA-mediated inhibition of T cell activation (16, 17).
In this study, lymph node cells from LP-BM5–infected RIAD-
transgenic mice and sex-matched wild-type littermates were stim-
ulated with soluble CD3 Ab and/or IL-2 for 72 h and proli-
feration assessed as [3H]thymidine incorporation. Proliferation in
response to soluble CD3 Ab alone, IL-2 alone, and soluble CD3
Ab and IL-2 in combination was significantly higher in the RIAD-
transgenic mice compared with sex-matched wild-type littermates.
In fact, lymph node cell proliferation in LP-BM5–infected RIAD-
transgenic mice was almost the same as in uninfected C57BL/6
control mice on stimulation with soluble CD3 Ab alone or in
combination with IL-2 (Fig. 6D). Thus, MAIDS-associated T cell
anergy is broken and T cell proliferative function maintained in
RIAD-transgenic mice.
Finally, LP-BM5 viral load in infected RIAD-transgenic mice
and sex-matched wild-type littermates was assessed as abundance
of BM5def mRNA relative to B2M mRNA by reverse transcription
and quantitative real-time PCR (Fig. 6E). Viral load was signifi-
cantly lower in LP-BM5–infected RIAD-transgenic mice com-
pared with LP-BM5–infected sex-matched wild-type littermates,
indicating improved ability to compete virus replication in the
RIAD-transgenic mice.
Development of MAIDS phenotypic characteristics is inhibited
in infected RIAD-transgenic mice
A large proportion of CD4+ T cells is characterized by an unusual
CD90.2 (Thy-1.2)-negative phenotype in LP-BM5–infected mice
compared with uninfected controls (42, 43) (Fig. 7A, middle and
left panels). We have previously shown that the loss of CD90.2
correlates with increased intracellular cAMP concentration and
activation of type I PKA (16). To examine the CD4+CD90.22
T cell population in LP-BM5–infected RIAD-transgenic mice,
lymph node cells from LP-BM5–infected RIAD-transgenic mice
and sex-matched wild-type littermates, as well as uninfected
C57BL/6 control mice, were stained with fluorochrome-conjugated
Ab to surface Ags and analyzed by flow cytometry. This revealed
a significantly smaller CD4+CD90.22 T cell population in LP-
BM5–infected RIAD-transgenic mice compared with in LP-BM5–
infected wild-type littermates (Fig. 7A, right and middle panels,
7B). Furthermore, MAIDS is associated with an expansion of
B cells expressing CD45R (B220) at low densities (CD45R dim
cells) (44) (Fig. 7C, middle and left panels). This expansion was
limited in LP-BM5–infected RIAD-transgenic mice (Fig. 7C, right
panel, 7D). CD11b, normally expressed on resting monocytes and
macrophages, is also upregulated on LP-BM5–infected T and
B cells (17) (Fig. 7E, middle and left panels). In LP-BM5–infected
RIAD-transgenic mice, however, the expression of CD11b on
B cells is limited (Fig. 7E, right panel, 7F). Finally, the expression
FIGURE 4. Enhanced T cell responses in RIAD-transgenic mice.
Splenic T cells from 4- to 5-mo-old RIAD-transgenic mice (Tg 11) and
sex-matched wild-type littermates (WT), n = 3–4, were stimulated by
CD3/CD28 cross-ligation for 20 h and secretion of cytokines measured by
ELISA (A) or multiplex assay (B–H).













of programmed death 1 (PD-1) on T cells is upregulated in LP-
BM5–infected wild-type mice (Fig. 7G, middle and left panels),
but the upregulation on T cells from LP-BM5–infected RIAD-
transgenic mice is limited (Fig. 7G, right panel, 7H). We con-
clude that the emergence of cell populations characteristic for
MAIDS is limited in infected RIAD-transgenic mice.
Discussion
In 2002, Williams (45) showed that incubation of mouse spleen
cells with the PKA anchoring disruptor peptide Ht31 leads to in-
creased IL-2, IL-4, IL-5, and IFN-g secretion, as well as enhanced
Ag-induced proliferation, suggesting that anchored PKA activity
was necessary for maintaining T cells in a resting state. Ht31-
treated mouse spleen cells were insensitive to the inhibitory ef-
fect of cAMP on IL-2 production, indicating that anchored PKA
activity was necessary for cAMP-mediated inhibition of T cell
function. cAMP modulates T cell immune function at multiple
levels through PKA (46). However, the importance of cAMP-type I
PKA-mediated inhibition of T cell activation has been demon-
strated by RIAD-mediated displacement of type I PKA from lipid
rafts, resulting in reduced phosphorylation of Lck Y505 (19).
Furthermore, knockdown of ezrin using RNA interference (9),
expression of mutant ezrin forms where type I PKA binding has
been abrogated by substitutions in the endogenous RISR sequence
(20) and loading of cells with a peptide that competes the ezrin–
EBP50 interaction (12) reversed cAMP-mediated suppression
of IL-2 production in primary human T cells. Likewise, pro-
teolytically stable RIAD peptidomimetics (47) and the RISR
peptide (20) prevented cAMP-mediated inhibition of primary hu-
man T cell function. Finally, specific activation of type I PKAwas
shown to be necessary and sufficient for mediating the inhibitory
effect of cAMP on proliferation of primary human T cells (3).
As stated, type I PKA is targeted to lipid rafts and the signaling
machinery immediately downstream of the TCR by ezrin (9). Ezrin
is a dual-specificity AKAP that contains two R binding regions:
the AKB, which is present in almost all AKAPs, and the upstream
RISR, which is present in dual-specificity AKAPs and serves to
enhance and specify binding to type I PKA. We have previously
shown by R overlay and amplified luminescence ligand proximity
assay (AlphaScreen) that when combined with RIAD, the RISR
enhances binding to RIa, and that a mutation in the ezrin en-
dogenous RISR (R381A) diminishes colocalization with RIa and
restores cAMP-mediated inhibition of IL-2 production in primary
human T cells (20). In this study, we engineered a construct di-
recting the expression of a soluble ezrin fragment with the en-
dogenous RISR and RIAD inserted in the position of the
endogenous AKB in mouse peripheral T cells. This RIAD fusion
protein retained RI selectivity and the capability to compete type I
PKA anchoring to lipid rafts and the proximal TCR signaling
machinery.
The RIAD-transgenic mice had increased peripheral T cell
counts. This may be partly explained by augmented activation of
Akt, which mediates T cell survival (48), in activated RIAD-
transgenic T cells. Furthermore, perturbation of the inhibitory
cAMP–type I PKA pathway leads to enhanced TCR-proximal
signaling and increased IL-2 secretion from activated T cells.
IL-2 promotes proliferation of T cells (49). However, despite the
increased T cell counts, spleens of RIAD-transgenic mice were
not enlarged. In addition, the percentage of B cells and mono-
cytes/macrophages were the same in RIAD-transgenic mice and
sex-matched wild-type littermates, as were the ratio of CD4+ to
CD8+ T cells and the fraction of Treg, but fewer other leukocytes,
erythrocytes, platelets, or parenchymal cells may allow for in-
creased T cell counts but unaltered spleen size.
Cyclic AMP-elevating or -mimicking agents inhibit production
of the Th1 cytokines IL-12, IFN-g, and IL-2, as well as TNF-a,
whereas production of the Th2 cytokines IL-4, IL-5, IL-6, and IL-
10 remains unchanged or even enhanced (18, 50–53). In line with
this, we did observe significantly increased secretion of IL-2 and
TNF-a, and in addition, a possible increased secretion of IL-12
and IFN-g, from activated RIAD-transgenic T cells. In contrast,
secretion of the Th2 cytokines IL-4 and IL-10 was unaffected or
possibly reduced. Williams (45) showed that incubation of mouse
spleen cells with the unspecific PKA anchoring disruptor Ht31
resulted in increased secretion of IFN-g, IL-2, IL-4, and IL-5 from
activated T cells. The discrepancies between our results and those
of Williams (45) may be because of the different cell populations
used and the fact that Ht31 disrupts anchoring of both type I and II
PKA, whereas the RIAD fusion protein specifically disrupts type I
PKA anchoring.
We demonstrate that peripheral T cells from RIAD-transgenic
mice are less sensitive to PGE2- and cAMP-mediated inhibition
of T cell function, and thus display a reduced threshold for acti-
vation. The RIAD-transgenic T cells are hyperreactive and hy-
perresponsive. Induction of cAMP levels in responder T cells,
either via secretion of PGE2 (54) or adenosine (55, 56) or via
FIGURE 5. Reduced sensitivity to cAMP-mediated inhibition of TCR-induced IL-2 secretion in peripheral T cells from RIAD-transgenic mice. A and B,
Splenic T cells from 6- to 8-wk-old RIAD-transgenic mice (Tg 11) and sex-matched wild-type littermates (WT) were incubated with increasing con-
centrations of 8-CPT-cAMP, stimulated by CD3/CD28 cross-ligation for 20 h, and subsequently analyzed for IL-2 secretion by ELISA. IC50 values were
estimated by nonlinear regression analyses in SigmaPlot (SPSS) as indicated. A, Representative experiment from one Tg 11/WT pair. B, Amalgamated data
from cAMP sensitivity analyses expressed as IC50 (8-CPT-cAMP) values (mean6 SEM). C, Splenic T cells from a 4- to 5-mo-old RIAD-transgenic mouse
(Tg 11) and a sex-matched wild-type littermate (WT) were incubated with increasing concentrations of PGE2, stimulated by CD3/CD28 cross-ligation for
20 h, and analyzed for IL-2 secretion by ELISA. IC50 values were estimated by nonlinear regression analyses in SigmaPlot (SPSS) as indicated.













direct intercellular transfer of cAMP by means of gap junctions
(57), has recently been appreciated as one of the mechanisms by
which Treg execute their suppressive action. It is therefore
tempting to speculate that RIAD-transgenic responder T cells may
be resistant to Treg-mediated suppression. Further investigation
will reveal whether this is indeed the case and also whether RIAD-
transgenic mice, with partly cAMP-resistant effector T cells, are
less prone to tumor development because of lack of local in-
hibition of antitumor immune activity by Treg. Furthermore, hy-
perreactive T cells and possible resistance to Treg-mediated
immune modulation could potentially lead to autoimmune dis-
ease in the RIAD-transgenic mice. However, no signs of sponta-
neous autoimmunity were seen in RIAD-transgenic mice main-
tained up to ∼2 y of age. Further investigation will be needed to
elucidate whether RIAD-transgenic mice display increased sus-
ceptibility to induced autoimmune diseases.
Hyperactivation of the cAMP–type I PKA pathway has been
implicated in the T cell dysfunction associated with HIV infection
(18) and a subset of common variable immunodeficiency (58), and
is also involved in the T cell dysfunction in MAIDS (16, 17).
Blocking this pathway by means of the type I PKA-specific an-
tagonist Rp-8-Br-cAMPS or cyclooxygenase inhibitors limiting
the production of PGE2 restores T cell function in vitro in MAIDS
(16, 17) and in HIV infection (18). In this article, we show that
T cell-specific type I PKA anchoring disruption limits the
splenomegaly and lymphadenopathy associated with MAIDS.
Furthermore, the MAIDS-associated abundance of CD4+CD90.22
T cells, CD45R dim B cells, CD45R+CD11b+ B cells, and CD3+
PD-1+ T cells is limited, T cell proliferative responses maintained,
and viral replication better controlled in the RIAD-transgenic
mice. The latter finding is particularly interesting and does sug-
gest that maintained T cell function indeed contributes to im-
proved viral control in MAIDS, a thought also supported by a
report showing that CTL play a crucial role in the resistance of
some mice strains to LP-BM5 infection (59). Some steps in the
viral cycle may depend on PKA activity. This is indeed the case in
HIV infection, where activation of the cAMP–PKA pathway has
been shown to increase virus transcription (60). In HIV infection,
undefined events involved in viral entry and infectivity are also
under control of PKA (61, 62). Finally, PKA-mediated phos-
FIGURE 6. Lower viral load and inhibited
development of MAIDS-associated spleno-
megaly, lymphadenopathy, and T cell anergy
in RIAD-transgenic mice. Six- to 8-wk-old
RIAD-transgenic mice and sex-matched wild-
type littermates were injected four times i.p.,
at 1-wk interval, with LP-BM5 (MAIDS Tg
11 and MAIDS WT, respectively). Age- and
sex-matched C57BL/6 control mice were
correspondingly injected with PBS (Uninf.).
The mice were sacrificed 8–9 wks after
the last injection (A, representative animals).
Spleens (B) and lymph nodes (C) (indicated
by arrows in A) were dissected and weighed.
D, Lymph node cells from LP-BM5–infected
RIAD-transgenic mice (MAIDS Tg 11) and
sex-matched wild-type littermates (MAIDS
WT), as well as age- and sex-matched un-
infected C57BL/6 control mice (Uninf.),
were stimulated with soluble CD3 Ab and/or
IL-2 for 72 h and proliferation assessed as
[3H]thymidine incorporation during the last
4 h (mean 6 SEM). E, RNA was extracted
from LP-BM5–infected RIAD-transgenic mice
(MAIDS Tg 11) and sex-matched wild-type
littermates (MAIDS WT) and age- and sex-
matched uninfected C57BL/6 control mice
(Uninf.), reversely transcribed, and abundance
of BM5def mRNA relative to B2M mRNA
was assessed by quantitative real-time PCR.













phorylation of the HIV-1 accessory proteins Nef and viral protein
R is necessary for HIV-1 pathology (63, 64). An approach tar-
geting the cAMP–type I PKA pathway could, therefore, have
several advantages in HIV infection, preserving innate and adap-
tative immune responses on the one hand, and directly limiting
infectivity on the other hand. Thus, our findings underscore the
inhibitory cAMP–type I PKA pathway in T cells as a putative
target for therapeutic intervention in T cell immunodeficiencies.
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